Catheter Precision, Inc. Earnings Per Share Disclosure

Note 10. Net Loss per Share

 

The Company’s Series X Convertible Preferred Stock, of which no shares were outstanding as of December 31, 2025, as well as the Series B Convertible Preferred Stock, Series J Convertible Preferred Stock, convertible notes payable, and outstanding warrants have participation rights to any dividends that may be declared in the future, such that they are participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. 

 

As a result of the net loss attributable to Catheter Precision, Inc.'s common stockholders for all periods presented herein, the following common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the years ended  December 31, 2025 and 2024 because including them would have been antidilutive:

 

		December 31,
		2025		2024
Warrants for common stock		1,418,943		870,500
Employee stock options		149,993		5,016
Series B Convertible Preferred Stock		335,213		—
Series J Convertible Preferred Stock		6,083,005		—
Series X Convertible Preferred Stock		—		66,580
Convertible notes payable		733,134		—
Total common stock equivalents		8,720,288		942,096

 

All common share and per-share amounts for all periods presented reflect the Company’s 1-for-19 reverse stock split effective on August 15, 2025.